Abstract
Translational medicine is intended to facilitate the transition of basic science results to clinical practice, thereby sharing major aspects of clinical pharmacology. Biomarkers need to be developed to achieve this, and their predictive values need to be assessed. Despite all the attempts to increase output from costly pharmaceutical research investments, all stakeholders complain of the decreasing efficiency of drug development processes, and expensive late attritions seem to be seen at increasing rates. How can translational medicine improve this apparent mismatch between effort and tangible result for daily medical practice? What is missing, and where do we stand?
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
FDA: Challenge and opportunity on the critical path to new medicines. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf
Boldyreff B, Wehling M (2004) Aldosterone: refreshing a slow hormone by swift action. News Physiol Sci 19:97–100
Frank R, Hargreaves R (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2:566–580
Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109(21 Suppl 1):II18–II26
Stahl A, Wieder H, Piert M, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M (2004) Positron emission tomography as a tool for translational research in oncology. Mol Imaging Biol 6:214–224
Rolan P, Atkinson AJ Jr, Lesko LJ, Scientific Organizing Committee, Conference Report Committee (2003) Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 73:284–291
Biomarkers Definitions Working Group Biomarkers and surrogate endpoints (2001) Preferred definitions and conceptual Framework. Clin Pharmacol Ther 69:89–95
Koek GH, Sifrim D, Lerut T, Janssens J, Tack J (2003) Effect of the GABAB agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52:1397–1402
Leyland-Jones B (2001) Maximizing the response to Herceptin therapy through optimal use and patient selection. Anticancer Drugs 12(Suppl)4:S11–S17
Bilello JA (2005) The agony and ecstasy of "OMIC" technologies in drug development. Curr Mol Med 5:39–52
Stoughton RB Friend SH (2005) How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov 4:345–350
Author information
Authors and Affiliations
Corresponding author
Additional information
The author is currently employed by AstraZeneca R&D while on leave from his professorship at the University of Heidelberg
Rights and permissions
About this article
Cite this article
Wehling, M. Translational medicine: can it really facilitate the transition of research “from bench to bedside”?. Eur J Clin Pharmacol 62, 91–95 (2006). https://doi.org/10.1007/s00228-005-0060-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0060-4